Harnessing Imaging Tools to Guide Immunotherapy Trials: Summary from the National Cancer Institute Cancer Imaging Steering Committee Workshop
2023 Mar
Journal Article
Authors:
Shankar, L.K.;
Schöder, H.;
Sharon, E.;
Wolchok, J.;
Knopp, M.V.;
Wahl, R.L.;
Ellingson, B.M.;
Hall, N.C.;
Yaffe, M.J.;
Towbin, A.J.;
Farwell, M.D.;
Pryma, D.;
Poussaint, T.Young;
Wright, C.L.;
Schwartz, L.;
Harisinghani, M.;
Mahmood, U.;
Wu, A.M.;
Leung, D.;
de Vries, E.G.E.;
Tang, Y.;
Beach, G.;
Reeves, S.A.
Secondary:
Lancet Oncol
Volume:
24
Pagination:
e133-e143
Issue:
3
PMID:
36858729
URL:
https://pubmed.ncbi.nlm.nih.gov/36858729/
DOI:
10.1016/S1470-2045(22)00742-2
Keywords:
Humans; Image Processing, Computer-Assisted; Immunotherapy; Medical Oncology; National Cancer Institute (U.S.); Neoplasms; United States
Abstract:
As the immuno-oncology field continues the rapid growth witnessed over the past decade, optimising patient outcomes requires an evolution in the current response-assessment guidelines for phase 2 and 3 immunotherapy clinical trials and clinical care. Additionally, investigational tools-including image analysis of standard-of-care scans (such as CT, magnetic resonance, and PET) with analytics, such as radiomics, functional magnetic resonance agents, and novel molecular-imaging PET agents-offer promising advancements for assessment of immunotherapy. To document current challenges and opportunities and identify next steps in immunotherapy diagnostic imaging, the National Cancer Institute Clinical Imaging Steering Committee convened a meeting with diverse representation among imaging experts and oncologists to generate a comprehensive review of the state of the field.
